Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate
antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This
planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation
Powder in the pediatric population of 6 to 12 years of age.